Cargando…

Targeted therapies in the management of renal cell carcinoma: role of bevacizumab

Bevacizumab (10 mg/kg every 2 weeks), in combination with interferon alpha-2a (IFN), is an effective option for first-line therapy for advanced and/or metastatic renal cell carcinoma (RCC). Two phase III trials clearly show significant improvements in progression-free survival and response rate in p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Escudier, Bernard, Cosaert, Jan, Jethwa, Sangeeta
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2008
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2721410/ https://www.ncbi.nlm.nih.gov/pubmed/19707382

Ejemplares similares

Axitinib for the Management of Metastatic Renal Cell Carcinoma
por: Escudier, Bernard, et al.
Publicado: (2012)

Targeted therapies in the management of colorectal carcinoma: role of bevacizumab
por: Puthillath, Ajithkumar, et al.
Publicado: (2009)

A serum metabolomic fingerprint of bevacizumab and temsirolimus combination as first-line treatment of metastatic renal cell carcinoma
por: Jobard, Elodie, et al.
Publicado: (2015)

Indirect treatment comparison of bevacizumab + interferon-α-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy
por: Mickisch, Gerald HJ, et al.
Publicado: (2011)

Role of bevacizumab therapy in the management of glioblastoma
por: Peak, Scott J, et al.
Publicado: (2010)

Reply: Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib
por: Mickisch, G H J, et al.
Publicado: (2010)

Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib
por: Mickisch, G, et al.
Publicado: (2010)

The bevacizumab experience in advanced renal cell carcinoma
por: Harshman, Lauren C, et al.
Publicado: (2010)

Hypertension and Angiotensin System Inhibitors in Patients with Metastatic Renal Cell Carcinoma
por: Derosa, Lisa, et al.
Publicado: (2016)

First-Line Targeted Therapy for Hepatocellular Carcinoma: Role of Atezolizumab/Bevacizumab Combination
por: Tella, Sri Harsha, et al.
Publicado: (2022)

Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors
por: Négrier, Sylvie, et al.
Publicado: (2017)

Targeted therapy of advanced non-small cell lung cancer: the role of bevacizumab
por: Stinchcombe, Thomas E
Publicado: (2007)

The Role of Targeted Therapy in Metastatic Renal Cell Carcinoma
por: Unnithan, Jaya, et al.
Publicado: (2007)

Metastatic clear cell carcinoma of the kidney: therapeutic role of bevacizumab
por: Bukowski, Ronald M
Publicado: (2010)

Rationale for targeted therapies and potential role of pazopanib in advanced renal cell carcinoma
por: Clark, Peter E
Publicado: (2010)

Immunotherapeutic Targets and Therapy for Renal Cell Carcinoma
por: Sepe, Pierangela, et al.
Publicado: (2020)

Lipids as Targets for Renal Cell Carcinoma Therapy
por: Stepanovska Tanturovska, Bisera, et al.
Publicado: (2023)

Platinum drugs in the treatment of non-small-cell lung cancer
por: Cosaert, J, et al.
Publicado: (2002)

Recent Advances in the Management of Clear Cell Renal Cell Carcinoma: Novel Biomarkers and Targeted Therapies
por: Schiavoni, Valentina, et al.
Publicado: (2023)

Therapeutic Targeting of Autophagy for Renal Cell Carcinoma Therapy
por: Jones, Trace M., et al.
Publicado: (2020)

First line targeted therapies in breast cancer: focus on bevacizumab
por: Milano, Amalia, et al.
Publicado: (2007)

The Emerging Role of Radiation Therapy in Renal Cell Carcinoma
por: Christensen, Michael, et al.
Publicado: (2022)

Combining Sunitinib and Bevacizumab for the Management of Advanced Renal Cell Carcinoma: A Phase I/II Trial
por: Bazarbashi, Shouki, et al.
Publicado: (2023)

Identification of international metastatic renal cell carcinoma database consortium (IMDC) intermediate-risk subgroups in patients with metastatic clear-cell renal cell carcinoma
por: Guida, Annalisa, et al.
Publicado: (2020)

Targeted therapy for renal cell carcinoma: The next lap
por: Kanesvaran, Ravindran, et al.
Publicado: (2014)

Role of Radiation Therapy in the Management of Renal Cell Cancer
por: Blanco, Angel I., et al.
Publicado: (2011)

Biomarkers in renal cell carcinoma and their targeted therapies: a review
por: Gupta, Shruti, et al.
Publicado: (2023)

Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma
por: Motzer, Robert J., et al.
Publicado: (2018)

Gynecologic bleeding revealing vaginal metastasis of renal cell carcinoma
por: Benbrahim, Zineb, et al.
Publicado: (2013)

The Role of the Cardiac Biomarkers in the Renal Cell Carcinoma Multidisciplinary Management
por: Drăgan, Anca, et al.
Publicado: (2023)

An Overview of Systemic Targeted Therapy in Renal Cell Carcinoma, with a Focus on Metastatic Renal Cell Carcinoma and Brain Metastases
por: Semenescu, Liliana Eleonora, et al.
Publicado: (2023)

Current Status of Targeted Therapy for Advanced Renal Cell Carcinoma
por: Cho, In-Chang, et al.
Publicado: (2012)

Progress of Molecular Targeted Therapies for Advanced Renal Cell Carcinoma
por: Conti, Alessandro, et al.
Publicado: (2013)

Targeted therapies for renal cell carcinoma in Chinese patients: focus on everolimus
por: Tan, Xiaojie, et al.
Publicado: (2015)

Fumarate hydratase-deficient renal cell carcinoma in extended remission with bevacizumab and erlotinib
por: Tomar, Shubham, et al.
Publicado: (2022)

Cell death-related molecules and biomarkers for renal cell carcinoma targeted therapy
por: Lai, Yongchang, et al.
Publicado: (2019)

Role of cytokine therapy for renal cell carcinoma in the era of targeted agents
por: Koneru, R., et al.
Publicado: (2009)

Targeted Therapy for Metastatic Renal Carcinoma: an Update
por: da Silva, Rodrigo Donalisio, et al.
Publicado: (2014)

Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean Patients
por: Choi, Yeonjoo, et al.
Publicado: (2019)

Remission of Psoriasis and Psoriatic Arthritis During Bevacizumab Therapy for Renal Cell Cancer
por: Datta-Mitra, Ananaya, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_d557ufgosrega14nhfvoobv5s9